Beth C. Seidenberg
CIK: 0001184592
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (22 total)
- Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect1M shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect2.1M shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect165.5K shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect1.5M shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect3.5M shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect939K shares- - Aug 10, 2026LTGO
Latigo Biotherapeutics, Inc.
Conversion(C)Indirect3.5M shares- - Jun 12, 2026SGMT
Sagimet Biosciences Inc.
Award(A)DirectStock Option (Right to Buy)
39.6K shares- - May 27, 2026KYTX
Kyverna Therapeutics, Inc.
Award(A)Direct5.1K shares- - May 21, 2026VERA
Vera Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
17.1K shares- - Dec 18, 2025KYTX
Kyverna Therapeutics, Inc.
Purchase(P)Indirect133.3K shares at avg. $7.50$1000K - Jun 9, 2025SGMT
Sagimet Biosciences Inc.
Award(A)DirectStock Option (Right to Buy)
32.3K shares- - Jun 6, 2025SGMT
Sagimet Biosciences Inc.
Award(A)DirectStock Option (Right to Buy)
28.5K shares- - May 29, 2025KYTX
Kyverna Therapeutics, Inc.
Award(A)Direct16.6K shares- - May 21, 2025SLRN
ACELYRIN, Inc.
Disposition(D)Indirect9.8M shares- - May 21, 2025SLRN
ACELYRIN, Inc.
Disposition(D)Direct60K shares- - May 14, 2025VERA
Vera Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
14K shares- - Oct 28, 2024VERA
Vera Therapeutics, Inc.
Sale(S)Direct14.8K shares at avg. $48.01$710K - Oct 28, 2024VERA
Vera Therapeutics, Inc.
Sale(S)Direct202 shares at avg. $49.54$10K - Sep 19, 2024VERA
Vera Therapeutics, Inc.
Sale(S)Direct13.8K shares at avg. $42.31$585K - Sep 18, 2024VERA
Vera Therapeutics, Inc.
Sale(S)Direct1.2K shares at avg. $42.01$49K - Sep 18, 2024VERA
Vera Therapeutics, Inc.
Sale(S)Indirect1.5K shares at avg. $42.00$62K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 10, 2026 |  LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 1,027,635 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 2,066,857 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 165,519 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 1,484,401 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 3,464,072 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 938,979 | - | $0 | Indirect |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Conversion(C) | 3,547,842 | - | $0 | Indirect |
| Jun 12, 2026 |  SGMT Sagimet Biosciences Inc. | Award(A) Stock Option (Right to Buy) | 39,567 | - | - | Direct |
| May 27, 2026 |  KYTX Kyverna Therapeutics, Inc. | Award(A) | 5,093 | - | $0 | Direct |
| May 21, 2026 |  VERA Vera Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 17,084 | - | - | Direct |
| Dec 18, 2025 | KYTX Kyverna Therapeutics, Inc. | Purchase(P) | 133,333 | $7.50 | $999,998 | Indirect |
| Jun 9, 2025 | SGMT Sagimet Biosciences Inc. | Award(A) Stock Option (Right to Buy) | 32,250 | - | - | Direct |
| Jun 6, 2025 | SGMT Sagimet Biosciences Inc. | Award(A) Stock Option (Right to Buy) | 28,522 | - | - | Direct |
| May 29, 2025 | KYTX Kyverna Therapeutics, Inc. | Award(A) | 16,634 | - | - | Direct |
| May 21, 2025 |  SLRN ACELYRIN, Inc. | Disposition(D) | 9,790,729 | - | - | Indirect |
| May 21, 2025 | SLRN ACELYRIN, Inc. | Disposition(D) | 60,000 | - | - | Direct |
| May 14, 2025 | VERA Vera Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 14,000 | - | - | Direct |
| Oct 28, 2024 | VERA Vera Therapeutics, Inc. | Sale(S) | 14,798 | $48.01 | $710,486 | Direct |
| Oct 28, 2024 | VERA Vera Therapeutics, Inc. | Sale(S) | 202 | $49.54 | $10,007 | Direct |
| Sep 19, 2024 | VERA Vera Therapeutics, Inc. | Sale(S) | 13,823 | $42.31 | $584,793 | Direct |
| Sep 18, 2024 | VERA Vera Therapeutics, Inc. | Sale(S) | 1,177 | $42.01 | $49,448 | Direct |
| Sep 18, 2024 | VERA Vera Therapeutics, Inc. | Sale(S) | 1,476 | $42.00 | $61,992 | Indirect |
1-22 of 22 transactions
About SEIDENBERG BETH C
SEIDENBERG BETH C (SEC CIK 0001184592) files insider reports with the SEC as Director of Latigo Biotherapeutics, Inc. (LTGO), Director of Sagimet Biosciences Inc. (SGMT) and Director of Kyverna Therapeutics, Inc. (KYTX). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 12 ownership filings by SEIDENBERG BETH C (1 Form 3, 11 Form 4), filed between Sep 20, 2024 and Aug 10, 2026. Those filings report 22 transactions, from Sep 18, 2024 to Aug 10, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on SEIDENBERG BETH C's filings is in THOUSAND OAKS, CA.
Recent filings by SEIDENBERG BETH C
- Aug 10, 2026: Conversions of LTGO shares (7 lines, Form 4, code C).
- Jun 12, 2026: Grant or award of SGMT derivative securities (Form 4, code A).
- May 27, 2026: Grant or award of KYTX shares (Form 4, code A).
- May 21, 2026: Grant or award of VERA derivative securities (Form 4, code A).
- Dec 18, 2025: Open-market purchase of KYTX shares (Form 4, code P).
Other insiders filing for Latigo Biotherapeutics, Inc. (LTGO)
- 5AM Ventures VI, L.P., 10% Owner
- Sanofi, 10% Owner
- Westlake BioPartners Fund I, L.P., 10% Owner
- Foresite Capital Management V, LLC, 10% Owner
- SMITH TODD N, Director
- Tananbaum James B., Director